Russia has developed an anti-cancer mRNA vaccine and will distribute it free of charge to patients, said Andrey Kaprin, Director General of the Russian Ministry of Health's X-ray Medicine Research Center to Radio Rossiya.
The vaccine was developed in cooperation with a number of research centers, and is expected to be launched on the market in early 2025.
Previously, Director of the National Center for Epidemiological and microbiological Research Gamaleya Alexander Gintsburg told TASS that preclinical studies of the cancer vaccine showed that the vaccine prevents the growth of tumors and potential metastasis.
"In the preclinical stage, we saw that the tumor (hugectomy) disappeared, and not only the tumor but also the metastasis disappeared. I do not rule out the possibility that we will have stage 4 cancer patients using this vaccine," RIA Novosti quoted Ginzburg as saying.
According to him, the Gamaleya Center, the National Center for Medical Cancer Research, along with a number of institutes and groups of scientists, have begun testing the vaccine's effects on a number of other types of cancer, such as lung, kidney and pancreatic cancer.
Previously, Mr. Ginzburg announced that the cancer vaccine was specifically produced for each patient. Artificial intelligence (AI) supports vaccine development, creating a drug diagram after analyzing tumor parameters. It can take only 7 days to create a drug.
Mr. Andrey Kaprin confirmed that clinical trials for the cancer vaccine have been completed and will be distributed free of charge to patients.
